



DATE: May 30, 2002 SHEET 1 of 1

TECH CENTER 1600/2900

JUN 06 2002

RECEIVED

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6791.US.02	SERIAL NO. 10/081,207
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT(S) <i>M. Cowart et al.</i>	
(Use several sheets if necessary)		FILING DATE February 25, 2002	GROUP ART NO. 1642
(37 CFR 1.98 (b))			

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	US 4,297,369	10/27/1981	Takizawa <i>et al.</i>	424	285	07/28/1980
	A2	US 4,447,620	05/08/1984	Sih <i>et al.</i>	548	336	10/12/1982
	A3	US 4,452,986	06/05/1984	Johnson <i>et al.</i>	548	336	09/30/1982
	A4	US 5,648,372	07/15/1997	Naito <i>et al.</i>	514	383	02/01/1995

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION
							YES NO
	B1	0 169 012 A1	22.01.1986	EP			
	B2	94/26738	24.11.1994	WO			
	B3	0 978 512 A1	09.02.2000	EP			
	B4	00/06254	10.02.2000	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	LEURS, R., <i>et al.</i> "Therapeutic potential of histamine H ₃ receptor agonists and antagonists", Trends in Pharmacological Sciences 1998, Vol. 19 (5), pp. 177-183 (May 1998)
C2	HAAS, H., <i>et al.</i> "Subcortical modulation of synaptic plasticity in the hippocampus", Behavioural Brain Research, Germany, Vol. 66, pp. 41-44 (Jan. 1995)
C3	SCHWARTZ, J., <i>et al.</i> "Histaminergic transmission in the mammalian brain", Physiological Reviews, France, Vol. 71, No. 1, pp. 1-51 (Jan. 1991)

EXAMINER _____ DATE CONSIDERED _____

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PATENT
TECH CENTER 1600/2900
JUN 06 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Cowart, et al.

Serial NO.: 10/081,207

Filed: February 25, 2002

Title: NOVEL AMINES AS HISTAMINE-3
RECEPTOR LIGANDS AND THEIR
THERAPEUTIC APPLICATIONS

Case No.: 6791.US.O2

Group Art No.: 1642

Examiner: (not yet assigned)

I hereby certify that this paper (along with any papers referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: May 30, 2002

Matthew H. Mader

Date

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,
M. Cowart, et al


Portia Chen
Registration No. 44,075
Attorney for Applicants


* 2 3 4 9 2 *
23492

ABBOTT LABORATORIES
Telephone: (847) 937-8272
Facsimile: (847) 938-2623

RECEIVED



0

X 1
8/9/02
L36/16/02
PARENT
TECH CENTER 1600/2800
JUN 06 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. Cowart, et al.

Serial No.: 10/081,207

Filed: February 25, 2002

Title: NOVEL AMINES AS HISTAMINE-3
RECEPTOR LIGANDS AND THEIR
THERAPEUTIC APPLICATIONS

Case No.: 6791.US.02

Group Art No.: 1642

Examiner: Not yet assigned

I hereby certify that this paper (along with paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the:

Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: May 29, 2002

 5/30/02
Matthew H. Mader DateCommissioner for Patents
Washington, D.C. 20231

Dear Sir:

TRANSMITTAL LETTER

Enclosed herewith for the patent application identified above entitled NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS are the following:

1. Information Disclosure Statement;
2. Form PTO-1449, in duplicate;
3. References as cited on PTO-1449 (11 References); and
4. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR § 1.16, as well as any patent application processing fees under 37 CFR § 1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.



23492

ABBOTT LABORATORIES
Telephone: (847) 937-8272
Facsimile: (847) 938-2623Respectfully submitted,
M. Cowart, et al.
Portia Chen
Registration No. 44,075
Attorney for Applicants